Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age

abstract

Purpose

To assess cost-effectiveness of routine screening for Lynch Syndrome (LS) in endometrial cancer (EC) patients ≤ 70 years of age.

Methods

Consecutive EC patients ≤ 70 years of age were screened for LS by analysis of microsatellite instability, immunohistochemistry and MLH1 hypermethylation. Costs and health benefit in life years gained (LYG) included surveillance for LS carriers among EC patients and relatives. We calculated incremental cost-effectiveness ratios (ICERs) comparing LS screening among EC patients ≤ 70 years with ≤ 50 years and the revised Bethesda guidelines.

Conclusion

Routine LS screening in EC patients ≤ 70 years is a cost-effective strategy, allowing colorectal cancer prevention in EC patients and their relatives.